Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Lipodystrophies-Disorders of the Fatty Tissue.

Tytuł:
Lipodystrophies-Disorders of the Fatty Tissue.
Autorzy:
Knebel B; German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany.; Institute for Clinical Biochemistry and Pathobiochemistry, 40225 Düsseldorf, Germany.; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany.
Müller-Wieland D; Clinical Research Center, Department of Internal Medicine I, University Hospital Aachen, 52074 Aachen, Germany.
Kotzka J; German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany.; German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Nov 20; Vol. 21 (22). Date of Electronic Publication: 2020 Nov 20.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Atherosclerosis/*genetics
Coronary Disease/*genetics
Diabetes Mellitus/*genetics
Fatty Liver/*genetics
Hypertriglyceridemia/*genetics
Lipodystrophy/*genetics
Acyltransferases/deficiency ; Acyltransferases/genetics ; Adipose Tissue/metabolism ; Adipose Tissue/pathology ; Animals ; Atherosclerosis/etiology ; Atherosclerosis/metabolism ; Atherosclerosis/pathology ; Body Fat Distribution ; Coronary Disease/etiology ; Coronary Disease/metabolism ; Coronary Disease/pathology ; Diabetes Mellitus/etiology ; Diabetes Mellitus/metabolism ; Diabetes Mellitus/pathology ; Disease Models, Animal ; Fatty Liver/complications ; Fatty Liver/metabolism ; Fatty Liver/pathology ; Humans ; Hypertriglyceridemia/complications ; Hypertriglyceridemia/metabolism ; Hypertriglyceridemia/pathology ; Insulin Resistance ; Lamin Type A/deficiency ; Lamin Type A/genetics ; Lipid Metabolism/genetics ; Lipodystrophy/complications ; Lipodystrophy/metabolism ; Lipodystrophy/pathology ; Pancreatitis/etiology ; Pancreatitis/genetics ; Pancreatitis/metabolism ; Pancreatitis/pathology ; Xanthomatosis/etiology ; Xanthomatosis/genetics ; Xanthomatosis/metabolism ; Xanthomatosis/pathology
References:
Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1097-104. (PMID: 19690066)
Hum Mol Genet. 2002 Apr 1;11(7):769-77. (PMID: 11929849)
Genes Dev. 1996 May 1;10(9):1096-107. (PMID: 8654925)
N Engl J Med. 2004 Mar 18;350(12):1220-34. (PMID: 15028826)
J Clin Endocrinol Metab. 2008 Apr;93(4):1129-34. (PMID: 18211975)
J Biol Chem. 2009 Dec 11;284(50):34538-44. (PMID: 19850935)
EMBO Mol Med. 2009 Aug;1(5):280-7. (PMID: 20049731)
Sci Transl Med. 2012 Jul 25;4(144):144ra103. (PMID: 22837538)
Diabetes. 2012 Nov;61(11):2922-31. (PMID: 22872237)
Hum Mol Genet. 2015 Apr 1;24(7):2096-109. (PMID: 25524705)
Mol Cell Biol. 2012 Mar;32(6):1099-111. (PMID: 22269949)
Nat Genet. 2002 May;31(1):21-3. (PMID: 11967537)
J Clin Endocrinol Metab. 2005 Mar;90(3):1446-52. (PMID: 15613417)
J Diabetes Investig. 2018 Sep;9(5):1224-1227. (PMID: 29476696)
Metabolism. 2017 Jul;72:A4-A10. (PMID: 28641789)
Cell Rep. 2020 Oct 6;33(1):108228. (PMID: 33027649)
Nature. 2003 May 15;423(6937):293-8. (PMID: 12714972)
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6494-9. (PMID: 11371650)
Hum Genet. 2018 Dec;137(11-12):921-939. (PMID: 30450527)
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7. (PMID: 14660788)
Nat Genet. 2001 Aug;28(4):365-70. (PMID: 11479539)
J Lipid Res. 2009 Nov;50(11):2306-13. (PMID: 19515989)
Diabetol Metab Syndr. 2017 Apr 24;9:26. (PMID: 28450900)
Diabetes. 2014 Jul;63(7):2320-31. (PMID: 24622797)
Diabetes Metab Syndr Obes. 2020 May 06;13:1531-1544. (PMID: 32440182)
J Clin Invest. 2008 Aug;118(8):2808-21. (PMID: 18654663)
Curr Stem Cell Res Ther. 2016;11(3):255-64. (PMID: 26027680)
Eur J Med Genet. 2014 Sep;57(9):524-6. (PMID: 24980513)
Nat Genet. 2000 Dec;26(4):474-9. (PMID: 11101849)
Can J Cardiol. 2014 Dec;30(12):1649-54. (PMID: 25475467)
Nat Rev Mol Cell Biol. 2020 Apr;21(4):183-203. (PMID: 31937935)
Annu Rev Cell Dev Biol. 2017 Oct 6;33:491-510. (PMID: 28793795)
J Clin Invest. 1996 Oct 1;98(7):1575-84. (PMID: 8833906)
Medicine (Baltimore). 2004 Jan;83(1):18-34. (PMID: 14747765)
Orphanet J Rare Dis. 2013 Aug 07;8:119. (PMID: 23919306)
J Clin Invest. 2006 Mar;116(3):581-9. (PMID: 16511590)
J Biol Chem. 1999 Oct 15;274(42):30028-32. (PMID: 10514488)
N Engl J Med. 2011 Feb 24;364(8):740-8. (PMID: 21345103)
Clin Dermatol. 2018 Jan - Feb;36(1):48-53. (PMID: 29241752)
Clin Sci (Lond). 2017 Jan 1;131(2):105-111. (PMID: 27974395)
J Clin Invest. 1997 Oct 15;100(8):2115-24. (PMID: 9329978)
Dan Med J. 2016 Oct;63(10):. (PMID: 27697134)
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8901-6. (PMID: 24889630)
Curr Top Dev Biol. 2014;109:53-96. (PMID: 24947236)
Nature. 2003 May 15;423(6937):298-301. (PMID: 12748643)
Biochemistry. 2003 Dec 23;42(50):14711-9. (PMID: 14674745)
Hum Mol Genet. 2012 Mar 1;21(5):1037-48. (PMID: 22090424)
Mol Cell. 1999 Oct;4(4):585-95. (PMID: 10549290)
Semin Cell Dev Biol. 2018 Sep;81:98-109. (PMID: 28736205)
Vet Pathol. 2011 May;48(3):642-54. (PMID: 21051554)
Endocrine. 2018 Jun;60(3):479-489. (PMID: 29644599)
Genes Dev. 1998 Oct 15;12(20):3168-81. (PMID: 9784492)
Elife. 2020 May 26;9:. (PMID: 32452759)
J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. (PMID: 27710244)
Metabolism. 2015 Jan;64(1):47-59. (PMID: 25267014)
Int J Biochem Cell Biol. 2010 Jun;42(6):785-8. (PMID: 20044026)
Nat Genet. 2000 Feb;24(2):153-6. (PMID: 10655060)
N Engl J Med. 2005 Jan 6;352(1):48-62. (PMID: 15635112)
IUBMB Life. 2004 Jul;56(7):379-85. (PMID: 15545214)
J Clin Invest. 2007 Mar;117(3):812-22. (PMID: 17304352)
Metabolism. 2020 Oct;111:154341. (PMID: 32810486)
Curr Diab Rep. 2018 Oct 29;18(12):139. (PMID: 30370487)
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14457-62. (PMID: 14603033)
J Biol Chem. 2004 Aug 20;279(34):35150-8. (PMID: 15197189)
J Med Case Rep. 2017 Jan 13;11(1):12. (PMID: 28086952)
J Clin Endocrinol Metab. 2002 Nov;87(11):4845-56. (PMID: 12414837)
J Clin Endocrinol Metab. 2009 Jan;94(1):10-6. (PMID: 18854390)
Nat Rev Endocrinol. 2017 Dec;13(12):710-730. (PMID: 28849786)
Diabetes. 2017 Aug;66(8):2241-2253. (PMID: 28490610)
Hum Mol Genet. 2003 Aug 15;12(16):1995-2001. (PMID: 12913070)
Metabolism. 2015 Jan;64(1):1-4. (PMID: 25497341)
Hum Mol Genet. 2000 Jan 1;9(1):109-12. (PMID: 10587585)
Science. 2004 May 28;304(5675):1325-8. (PMID: 15166380)
Genome Biol. 2004;5(6):226. (PMID: 15186484)
J Clin Invest. 1997 Mar 1;99(5):846-54. (PMID: 9062341)
N Engl J Med. 2014 Jun 12;370(24):2307-2315. (PMID: 24848981)
Diabet Med. 2017 Dec;34(12):1792-1794. (PMID: 29044799)
PLoS Genet. 2010 Mar 12;6(3):e1000874. (PMID: 20300641)
Biochem Biophys Res Commun. 2008 Sep 19;374(2):365-8. (PMID: 18639527)
Metabolism. 2013 Sep;62(9):1199-205. (PMID: 23706880)
Medicine (Baltimore). 2003 Mar;82(2):129-46. (PMID: 12640189)
J Clin Invest. 2009 Sep;119(9):2623-33. (PMID: 19726876)
Am J Hum Genet. 2002 Aug;71(2):426-31. (PMID: 12075506)
Cell Metab. 2009 Feb;9(2):165-76. (PMID: 19187773)
Am J Hum Genet. 2013 Jul 11;93(1):141-9. (PMID: 23810378)
Diabetes Care. 2003 Jun;26(6):1819-24. (PMID: 12766116)
Mol Biol Rep. 2019 Dec;46(6):6485-6494. (PMID: 31571108)
Am J Med Genet A. 2015 Aug;167A(8):1796-806. (PMID: 25898808)
PLoS One. 2012;7(2):e32609. (PMID: 22384276)
Genes Dev. 1998 Oct 15;12(20):3182-94. (PMID: 9784493)
PLoS One. 2012;7(2):e31812. (PMID: 22363740)
Contributed Indexing:
Keywords: acquired; generalized; genetics; lipodystrophy
Substance Nomenclature:
0 (LMNA protein, human)
0 (Lamin Type A)
EC 2.3.- (Acyltransferases)
EC 2.3.1.52 (2-acylglycerophosphate acyltransferase)
Entry Date(s):
Date Created: 20201125 Date Completed: 20210308 Latest Revision: 20210308
Update Code:
20240105
PubMed Central ID:
PMC7699751
DOI:
10.3390/ijms21228778
PMID:
33233602
Czasopismo naukowe
Lipodystrophies are a heterogeneous group of physiological changes characterized by a selective loss of fatty tissue. Here, no fat cells are present, either through lack of differentiation, loss of function or premature apoptosis. As a consequence, lipids can only be stored ectopically in non-adipocytes with the major health consequences as fatty liver and insulin resistance. This is a crucial difference to being slim where the fat cells are present and store lipids if needed. A simple clinical classification of lipodystrophies is based on congenital vs. acquired and generalized vs. partial disturbance of fat distribution. Complications in patients with lipodystrophy depend on the clinical manifestations. For example, in diabetes mellitus microangiopathic complications such as nephropathy, retinopathy and neuropathy may develop. In addition, due to ectopic lipid accumulation in the liver, fatty liver hepatitis may also develop, possibly with cirrhosis. The consequences of extreme hypertriglyceridemia are typically acute pancreatitis or eruptive xanthomas. The combination of severe hyperglycemia with dyslipidemia and signs of insulin resistance can lead to premature atherosclerosis with its associated complications of coronary heart disease, peripheral vascular disease and cerebrovascular changes. Overall, lipodystrophy is rare with an estimated incidence for congenital (<1/1.000.000) and acquired (1-9/100.000) forms. Due to the rarity of the syndrome and the phenotypic range of metabolic complications, only studies with limited patient numbers can be considered. Experimental animal models are therefore useful to understand the molecular mechanisms in lipodystrophy and to identify possible therapeutic approaches.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies